GenomiCare Biotechnology

GenomiCare Biotechnology is a Chinese precision cancer medicine service company founded in 2015. The company's slogan, "Empowering Chinese cancer patients and doctors with personalized clinical precision medicine solutions and medical resources," reflects its core mission. GenomiCare Biotechnology specializes in providing personalized clinical precision medicine solutions and medical resources for Chinese cancer patients and doctors. In December 2018, the company received a significant $30.00M Series A investment from General Oriental Investments, TrustBridge Partners, and GP Healthcare Capital. This investment not only underscores the potential of GenomiCare Biotechnology in the biotechnology and healthcare industries but also highlights the confidence that major investors have in the company's vision and capabilities. As GenomiCare Biotechnology continues to make strides in empowering Chinese cancer patients and doctors with personalized clinical precision medicine solutions, the recent investment stands as a testament to the company's potential for growth and impact in the Chinese healthcare sector. With the backing of notable investors and a clear focus on leveraging biotechnology for improved patient outcomes, GenomiCare Biotechnology is positioned for significant growth and influence in the coming years.